Mesenchymal Stem Cell Transplantation in MS (CMM-EM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01228266

Recruitment Status : Terminated (Ended the recruitment in June 2012 for low enrollement accrual)

First Posted : October 26, 2010

Last Update Posted : February 13, 2014

Sponsor:

Collaborator:

Instituto de Salud Carlos III

Information provided by (Responsible Party):

Albert Saiz, Hospital Clinic of Barcelona

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	June 2013
Actual Study Completion Date :	December 2013

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection 2014.

To Top